Key Highlights

  • FY26 Revenue increased 13% to AUD 10.87bn.
  • Underlying EBITDA rose 11% to AUD 1.93bn.
  • Net profit after tax increased 17% to AUD 621mn.
  • Sonic guided to FY27 underlying EBITDA of AUD 1.95bn to AUD 2.03bn.

Sonic Healthcare spent FY26 expanding its scale while absorbing a major German acquisition. Sonic Healthcare (ASX:SHL) reported higher revenue, EBITDA and net profit as LADR joined its laboratory network and organic revenue advanced. The next phase centres on completing integration work while managing reimbursement changes, labour expenses and an operating review in the United States.

Company Business

Sonic provides pathology and clinical laboratory services across Australia, Germany, the United States, the United Kingdom, Switzerland, Belgium and New Zealand. It also operates radiology and primary-care businesses in Australia. Local medical Leadership and established regional brands sit within a broader group structure that supports procurement, laboratory systems, Investment and Acquisition integration.

Sector Context

Sonic reported its FY26 result on 20 August 2026. Revenue of AUD 10,867mn was up 13%, underlying EBITDA of AUD 1,933mn rose 11%, and net profit after tax of AUD 621mn was 17% higher. Earnings Per Share came in at 125.6 cents, up 14%.

The board declared a final Dividend of 63 cents per share, taking the FY26 total to AUD 1.08, an increase of 0.9% and franked at 60%. Group organic revenue growth was reported at 5% on a constant currency basis. Germany was the standout, with revenue of AUD 2,729mn up 43% on a statutory basis and 5% organically, reflecting the LADR acquisition completed on 1 July 2025; Sonic reported capturing more than 40% of expected synergies in the first year.

Australian pathology revenue of AUD 2,184mn grew 5% organically. The United States contributed AUD 2,048mn, down 3% statutory and broadly flat in constant currency, with an operating review under way. UK revenue grew 17% in constant currency and Switzerland 4%.

Net interest-bearing Debt was AUD 3,069mn against AUD 2,818mn a year earlier, equating to 2.2 times EBITDA versus a 3.5 times covenant, with gearing of 25.9%. The group also completed a AUD 445mn sale and leaseback of its Brisbane hub with Charter Hall. For context, FY2025 revenue was about AUD 9.6bn with net profit of AUD 514mn.

Risks to Consider

Diagnostics revenue depends heavily on government and insurer reimbursement, and the Swiss fee changes show how quickly a regulator can reset pricing. Integration of a large acquisition can absorb management attention and cost more than planned. The group carries meaningful debt in a higher rate environment, earns a large share of profit offshore and so is exposed to currency movements, and faces wage Inflation across labour-intensive laboratory networks.

What to Watch Next

Management guided to FY27 underlying EBITDA of AUD 1,950-2,030mn in constant currency, excluding roughly AUD 30mn of IT transformation costs. Delivery against that range is the obvious marker. Beyond it, the pace of remaining LADR synergy capture, the outcome of the United States operating review, Margin recovery on the UK HWE contract and the estimated CHF20 million Swiss regulatory fee reduction are each identifiable items.

Australian Medicare indexation of 2.4% and Fair Work cost increases will also shape domestic margins. Sonic Healthcare enters the back half of 2026 with FY26 revenue of AUD 10.9bn, profit growth of 17% and a Balance Sheet inside its covenants. The harder part of the story is the FY27 guide, which implies more modest growth as Swiss pricing, UK integration and the US review work through.

Those are specific, trackable items — and they are why Sonic could remain one of the ASX healthcare names investors keep under review.